Tutkijat / Institutions  | Aarnio, M(arkku) (KSSHP) |
| Alafuzoff, I. (Uppsala) |
| Aro, A. (THL) |
| Aromaa, A. (THL) |
| Arvas, M(ikko) (Veripalvelu) |
| Bamford, D.H. (UH Viikki Campus) |
| Butcher, S. (UH Viikki Campus) |
| Cerullo, V. (UH Viikki Campus) |
| Ekblom-Kullberg, S(usanne) (Veripalvelu) |
| Eskola, J. (THL) |
| Finel, M(oshe) (UH Viikki Campus) |
| Gahmberg, C.G. (UH Viikki Campus) |
| Haimila, K(atri) (Veripalvelu) |
| Häkkinen, U. (THL) |
| Hanski, I(lkka) (1953-2016) (UH Viikki Campus) |
| Hari, R. (Aalto) |
| Havulinna, A(ki) S. (THL) |
| Hemminki, E. (THL) |
| Hiltunen, L(eena) (Veripalvelu) |
| Hiltunen, R(aimo) (UH Viikki Campus) |
| Holthöfer, H. (CBAS, Dublin) |
| Hovi, T. (THL) |
| Huoponen, O(uti) (Veripalvelu) |
| Huovinen, P. (THL) |
| Hyytiä, P. (THL) |
| Impola, U(lla) (Veripalvelu) |
| Jaatinen, T(aina) (Veripalvelu) |
| Jacobs, H.T. (UH Viikki Campus) |
| Jalanko, A. (THL) |
| Jalkanen, J(yrki) (KSSHP) |
| Jantunen, M. (THL) |
| Javela, K(aija) (Veripalvelu) |
| Joensuu, T(imo) (Docrates Cancer Center) |
| Jokela, J(orma) (Laurea) |
| Jokitalo, E. (UH Viikki Campus) |
| Jousilahti, P(ekka) (THL) |
| Julkunen, I. (THL) |
| Juppo, A(nne) (UH Viikki Campus) |
| Kääriäinen, H. (THL) |
| Kaartinen, T(anja) (Veripalvelu) |
| Kairemo, K(alevi) (Docrates) |
| Kallioniemi, O(lli) (SciLifeLab) |
| Karvonen, M. (THL) |
| Kayhty, H. (THL) |
| Kerkelä, E(rja) (Veripalvelu) |
| Keskimäki, I. (THL) |
| Kiianmaa, K. (THL) |
| Kinnunen, P.K. (Aalto) |
| Kirjavainen, V(esa) (Veripalvelu) |
| Klaukka, T. (Kela) |
| Korhonen, M(atti) (Veripalvelu) |
| Koskela, S(atu) (Veripalvelu) |
| Koskinen, S(eppo) (THL) |
| Kovanen, P.T. (Wihuri) |
| Kyrölä, K(ati) (KSSHP) |
| Laatikainen, T(iina) (THL) |
| Lähteenmäki, K(aarina) (Veripalvelu) |
| Laitinen, S(aara) (Veripalvelu) |
| Lappalainen, P. (UH Viikki Campus) |
| Larjo, A(ntti) (Veripalvelu) |
| Lauronen, J(ouni) (Veripalvelu) |
| Lehtinen, M(atti) (THL) |
| Leino-Arjas, P. (TTL) |
| Leinonen, M. (THL) |
| Lindros, K. (THL) |
| Linjama, T(iina) (Veripalvelu) |
| Lönnqvist, J. (THL) |
| Mäkelä, M. (THL) |
| Mäkelä, P.H. (THL) |
| Malmivaara, A(ntti) (THL) |
| Männistö, P. (UH Viikki Campus) |
| Mattila, P. (PSHP) |
| Mattila, P(irkko) (Veripalvelu/FIMM) |
| Mättö, J(aana) (Veripalvelu) |
| Natunen, S(uvi) (Veripalvelu) |
| Nissinen, A. (THL) |
| Nystedt, J(ohanna) (Veripalvelu) |
| Ovaskainen. M.L (THL). |
| Palosuo, T. (THL) |
| Palva, A(iri) (UH Viikki Campus) |
| Partanen, J(ukka) (Veripalvelu) |
| Partonen, T. (THL) |
| Patja, K. (THL) |
| Peltonen, M(arkku) (THL) |
| Peräsaari, J(uha) (Veripalvelu) |
| Pietinen, P. (THL) |
| Prattala, R. (THL) |
| Puska, P. (THL) |
| Qiao, Q(ing) (THL) |
| Reunanen, A. (THL) |
| Riihimäki, H. (TTL) |
| Ritari, J(armo) (Veripalvelu) |
| Ruotsalainen, P. (THL) |
| Ruskoaho, H(eikki) (UH Viikki Campus) |
| Ruutu, P. (THL) |
| Saarma, M. (UH Viikki Campus) |
| Saarni, S.I. (THL) |
| Saikku, P. (THL) |
| Sainio, S(usanna) (Veripalvelu) |
| Salomaa, V(eikko) (THL) |
| Shimmi, O. (UH Viikki Campus) |
| Siitonen, A. (THL) |
| Solantaus, T. (THL) |
| Thesleff, I. (UH Viikki Campus) |
| Tuomisto, J. (THL) |
| Uutela, A. (THL) |
| Vaarala, O. (THL) |
| Valsta, L. (THL) |
| Vartiainen, E(rkki) (THL) |
| Vartiainen, T. (THL) |
| Vasankari, T(ommi) (UKK) |
| Viikari-Juntura, E. (TTL) |
| Virtamo, J. (THL) |
| Virtanen, S.M. (THL) |
| Vuopio, J. (THL) |
| Wahlbeck, K. (THL) |
| Wikström, M. (UH Viikki Campus) |
Scholar Chart >>
|
»My Articles
»Latest Feeds
»Popular Feeds |
| | Preterm birth rate after bivalent HPV vaccination: Registry-based follow-up of a randomized clinical trial | Lehtinen, M(atti) (THL) | 47 days | save |  |  |  |  |
| Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: population-based registry study from Finland | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| The EACTS Residents Committee | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Sustained Cross-Reactive Antibody Responses After Human Papillomavirus Vaccinations: Up To 12 Years Follow-Up In The Finnish Maternity Cohort | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Efficacy of AS04-adjuvanted HPV-16/18 vaccine against clearance of incident HPV infections: Pooled analysis of data from the CVT and PATRICIA randomized trials | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| ESTIMATION OF HP(3) AMONG STAFF MEMBERS IN TWO NUCLEAR MEDICINE UNITS IN FINLAND | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| The Age-Specific Cervical Cancer Incidence Differs Between Human Papillomavirus Types: Implications for Predicting the Impact of Elimination Programs | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Long-term follow-up of human papillomavirus type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Impact of HPV vaccination on cervical screening performance: a population-based cohort study | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries - The ADVANCE project | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Human papillomavirus genotype replacement: still too early to tell? | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| The Prevalence of HSV, HHV-6, HPV and <em>Mycoplasma genitalium</em> in <em>Chlamydia trachomatis</em> positive and <em>Chlamydia trachomatis</em> Negative Urogenital Samples among Young Women in Finland | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Is the risk of cervical atypia associated with the interval between menarche and the start of sexual activity? A population-based cohort study | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Premedication with intranasal dexmedetomidine decreases barbiturate requirement in pediatric patients sedated for magnetic resonance imaging: a retrospective study | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV) | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Fast approximate computation of cervical cancer screening outcomes by a deterministic multiple-type HPV progression model | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Superselective endovascular tissue access using trans-vessel wall technique: feasibility study for treatment applications in heart, pancreas and kidney in swine | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Which human papillomavirus vaccine and vaccination strategy for national programs? | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III) | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Potential occupational exposures in diagnostic and interventional radiology: statistical modeling based on Finnish national dose registry data | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| The risk of cervical atypia in oral contraceptive users | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II) | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Vaccination protects against invasive HPV-associated cancers | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Cancer Registry follow-up for 17 million person-years of a nationwide maternity cohort | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I) | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Universal Janus Filters for the Rapid Separation of Oil from Emulsions Stabilized by Ionic or Nonionic Surfactants | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of <em>three cohorts from randomized trials</em> | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| Population-Based Study of Prediagnostic Antibodies to Chlamydia trachomatis in Relation to Adverse Pregnancy Outcome | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| EXPERIENCES IN DEVELOPING A NATIONAL DOSE REGISTER IN FINLAND AND MERGING IT WITH THE OVERALL SUPERVISORY DATA SYSTEM | Lehtinen, M(atti) (THL) | 55 days | save | | | | |
| | 
report | next » | | |
|
